Open an Account
search icon
4
NOTIFICATIONS
Best Algo trading app in India
Bigul

JAGSONPAL PHARMACEUTICALS LTD. - 507789 - Closure of Trading Window

 In terms of SEBI (Prohibition of Insider Trading) Regulations, 2015 and Company''s Code of Conduct to regulate, monitor and report trading by designated persons and Immediate relatives of Designated Persons, the Trading Window for dealing in securities of Jagsonpal Pharmaceuticals Limited ("the Company") shall remain closed for Designated Persons and their Immediate relatives(s) with effect from Saturday, July 01, 2023 till the end of 48 hours after the declaration of unaudited financial results for the quarter ended June 30, 2023. The date of the Meeting of Board of Directors of the Company at which the aforesaid Financial Results are to be approved, will be intimated to the Stock Exchange in due course.
29-06-2023
Bigul

JAGSONPAL PHARMACEUTICALS LTD. - 507789 - Compliances-Reg.24(A)-Annual Secretarial Compliance

 Pursuant to Regulation 24A of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFD/CMD1//27/2019 dated February 8, 2019, please find enclosed the Annual Secretarial Compliance Report for the Financial Year ended March 31, 2023.
30-05-2023

Jagsonpal Fin Standalone March 2023 Net Sales at Rs 0.02 crore, up 176.92% Y-o-Y
30-05-2023
Bigul

JAGSONPAL PHARMACEUTICALS LTD. - 507789 - Announcement under Regulation 30 (LODR)-Newspaper Publication

 Pursuant to the provision of Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed copies of advertisement published on May 25, 2023, in 'Business Standard' (English) and 'Business Standard' (Hindi) newspaper providing Extracts of Audited Financial Results of the Company for the quarter and year ended March 31, 2023.
25-05-2023
Bigul

JAGSONPAL PHARMACEUTICALS LTD. - 507789 - Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS

 Intimation of grant of Employee Stock Options
24-05-2023
Bigul

JAGSONPAL PHARMACEUTICALS LTD. - 507789 - Related Party Transactions For The Half Year Ended From October 01, 2022 To March 31, 2023

 Pursuant to Regulation 23(9) of the SEBI Listing Regulations, please find enclosed herewith disclosures of related party transactions in the revised format, as prescribed under SEBI Circular No. SEBI/HO/CFD/CMD1/CIR/P/2021/662 dated 22" November 2021, for the half year ended commencing from 01 October, 2022 to 31 March, 2023.
23-05-2023
Bigul

JAGSONPAL PHARMACEUTICALS LTD. - 507789 - Corporate Action-Board to consider Dividend

 The Board of Directors at their meeting held today have recommended dividend of Rs. 5/- per equity share of face value of Rs. 5/- for the financial year ended March 31, 2023. The dividend shall be payable after it is approved by the shareholders at the 44th Annual General Meeting of the Company.
23-05-2023
Bigul

JAGSONPAL PHARMACEUTICALS LTD. - 507789 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

 In terms of regulation 30 of the SEBI (LODR) Regulations, 2015, please find enclosed Press Release and Investor Presentation, being issued by the Company for the financial results for the quarter and year ended March 31, 2023. We request you to take the above on record.
23-05-2023
Bigul

JAGSONPAL PHARMACEUTICALS LTD. - 507789 - Outcome Of Board Meeting Held On May 23, 2023 Along With Audited (Standalone) Financial Results For The Quarter And Year Ended March 31, 2023

 Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the Board of Directors at its Meeting held today, inter-alia, considered and approved the Audited (Standalone) Financial Results for the quarter and year ended March 31, 2023. In this regard, kindly find enclosed the following: 1. Audited (Standalone) Financial Results along with Independent Auditor's Review Report issued by the Statutory Auditors of the Company for the quarter and year ended March 31, 2023. 2. The Board recommended a dividend of Rs. 5/- per equity share for the financial year ended March 31, 2023. The Board Meeting commenced at 11:15 a.m. and concluded at 2:20 p.m.
23-05-2023
Bigul

JAGSONPAL PHARMACEUTICALS LTD. - 507789 - Board Meeting Outcome for Outcome Of Board Meeting Held On May 23, 2023 Along With Audited (Standalone) Financial Results For The Quarter And Year Ended March 31, 2023

 Pursuant to Regulation 30 (read with Part A of Schedule III) and Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the Board of Directors at its Meeting held today, inter-alia, considered and approved the Audited (Standalone) Financial Results for the quarter and year ended March 31, 2023. In this regard, kindly find enclosed the following: 1. Audited (Standalone) Financial Results along with Independent Auditor's Review Report issued by the Statutory Auditors of the Company for the quarter and year ended March 31, 2023. 2. The Board recommended a dividend of Rs. 5/- per equity share for the financial year ended March 31, 2023.
23-05-2023
Next Page
Close

Let's Open Free Demat Account